8-K: Carisma Therapeutics Prioritizes CT-0525, Reports Q1 2024 Financials and Pipeline Updates

Carisma Therapeutics announced its first quarter 2024 financial results, highlighted the prioritization of its CT-0525 program, and provided updates on its clinical and preclinical programs.

Summary

• Carisma Therapeutics reported a net loss of $19.0 million for the first quarter of 2024, compared to a $24.6 million loss in the same period of 2023.
• The company's cash and cash equivalents were $56.5 million as of March 31, 2024, down from $77.6 million at the end of 2023.
• Research and development expenses increased to $17.5 million, while general and administrative expenses decreased to $5.4 million.
• Carisma has prioritized CT-0525, an anti-HER2 CAR-Monocyte therapy, as its lead product candidate, expecting initial data by year-end 2024.
• The company has paused development of CT-1119, an anti-Mesothelin CAR-Monocyte, pending additional financing.
• Preclinical data for engineered macrophages in liver fibrosis showed a 116% reduction in fibrosis in one model and a 45% reduction in another model, with a development candidate expected in the first quarter of 2025.
• A workforce reduction of approximately 37% was implemented in the second quarter of 2024 as part of a corporate restructuring.
• The company expects its current cash to fund operations into the third quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive preclinical data and a strategic shift towards a promising lead candidate, but also includes negative aspects such as a workforce reduction, decreased cash reserves, and the pausing of a development program. The overall sentiment is neutral to slightly negative.

Positives

• The prioritization of CT-0525 could lead to more effective anti-tumor activity.
• Preclinical data for engineered macrophages in fibrosis is promising, showing significant reductions in liver and lung fibrosis.
• The company's cash runway extends into the third quarter of 2025, providing financial stability.
• The appointment of a new Chief Medical Officer and a new board member brings valuable experience to the company.
• The company has reduced its net loss compared to the same period last year.

Negatives

• The company has paused development of CT-1119 pending additional financing.
• Recruitment of new patients into the CT-0508 study has been stopped.
• The company has reduced its workforce by approximately 37%.
• Cash reserves have decreased from $77.6 million to $56.5 million in the quarter.
• The company reported a net loss of $19.0 million for the quarter.

Risks

• The company's ability to obtain additional financing to continue development of CT-1119 is uncertain.
• The success of CT-0525 is not guaranteed, and clinical trial results may not be positive.
• The company's reduced workforce may impact its ability to execute its plans.
• The company's cash reserves are decreasing, and it may need to raise additional capital in the future.
• There are risks associated with the development of novel cell therapies, including regulatory hurdles and clinical trial challenges.

Future Outlook

Carisma anticipates that its cash and cash equivalents of $56.5 million as of March 31, 2024, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.

Management Comments

• We enter the second quarter with a renewed focus on our programs that we believe exhibit the greatest potential and meaningful near-term milestones, said Steven Kelly, President and Chief Executive Officer of Carisma.
• We are pleased by the continued clinical validation of our anti-HER2 CAR-M program as evidenced by the initial data from CT-0508 and are excited to shift our attention to the development of CT-0525, which we believe has the potential to significantly increase anti-tumor activity.
• The preclinical proof of concept data in liver fibrosis fuels our momentum to explore the potential of engineered macrophages beyond oncology.

Industry Context

The prioritization of CT-0525 reflects a trend in the cell therapy field towards optimizing CAR designs for improved efficacy and safety. The focus on engineered macrophages for fibrosis also highlights the growing interest in cell therapies beyond oncology. The company's restructuring and workforce reduction are indicative of the challenges faced by many biotech companies in managing resources and prioritizing programs.

Comparison to Industry Standards

• Carisma's shift to prioritize CT-0525 is similar to other companies focusing on lead candidates with the most potential, such as Kite Pharma's focus on their CAR-T therapies.
• The preclinical results in liver fibrosis are comparable to other companies exploring cell therapies for non-oncology indications, such as Lyell Immunopharma's work in solid tumors and fibrosis.
• The 37% workforce reduction is a significant restructuring, similar to other biotech companies that have faced financial pressures, such as the layoffs at companies like Sangamo Therapeutics.
• The cash runway into Q3 2025 is a common goal for clinical-stage biotechs, with companies like Allogene Therapeutics also aiming for similar timelines.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the company's restructuring and pipeline reprioritization.
• Employees have been impacted by the workforce reduction.
• Patients may benefit from the development of CT-0525 and other therapies.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• The company expects to treat the first patient in the CT-0525 Phase 1 clinical study in the second quarter of 2024.
• The company expects to report initial data from the CT-0525 study by year-end 2024.
• The company expects to report data from Regimen Level 2 in the CT-0508 study in the second quarter of 2024.
• The company expects to nominate a development candidate for its liver fibrosis program in the first quarter of 2025.

Key Dates

Keywords

CAR-Monocyte, CAR-Macrophage, Immunotherapy, Cell Therapy, HER2, Fibrosis, CT-0525, CT-0508, Clinical Trial, Biopharmaceutical